The United States Food and Drug Administration (FDA) has granted approval for Lenacapavir, an innovative, long-acting injectable drug, for HIV prevention. This decision represents a significant step in global HIV prevention and creates new opportunities to curb the spread of the virus. However, its high price and accessibility issues remain major obstacles on a global scale.
Lenacapavir’s Innovative Technology and Prevention Revolution
Lenacapavir marks a true breakthrough in HIV prevention. It is the first and only long-acting capsid inhibitor, distinguished by its unique mechanism of action. Specifically, it prevents HIV replication at various stages, including the transport of viral DNA into the nucleus, and the assembly and maturation of the virus.
Particularly noteworthy is its dosing interval – an injection is administered only once every six months. This radically differs from currently available standard oral drugs for HIV prevention, which require daily intake. Such infrequent dosing for Lenacapavir significantly simplifies the drug regimen and increases treatment (prevention) adherence, meaning how regularly people take the medication. This is critically important in high-risk groups and in situations where daily medication intake poses difficulties (e.g., due to stigma, forgetfulness, or challenges in maintaining a routine).
Clinical Trial Results and Efficacy
Lenacapavir’s unprecedented efficacy and safety are confirmed by the results of large-scale clinical trials, including the PURPOSE 1 and PURPOSE 2 studies.
The PURPOSE 1 study was conducted among women and adolescent girls at high risk of HIV infection in South Africa and Uganda. This geographical location lends particular importance to the study, as African countries remain the regions most affected by the HIV epidemic. The study showed that Lenacapavir was 100% effective in preventing HIV, meaning none of the participants receiving the drug developed HIV infection during the study period.
The PURPOSE 2 study also proved effective in other high-risk groups susceptible to HIV infection, further confirming the drug’s broad potential. In terms of safety, Lenacapavir was generally well-tolerated by patients, with side effects mostly mild to moderate. Its long-acting profile reduces potential toxicity from frequent dosing, which is another advantage.
Price and Accessibility Challenges
Despite its undeniable effectiveness, Lenacapavir’s high price is a significant global challenge. On the U.S. market, the drug’s market price is approximately $28,000 USD per year, making it inaccessible to the majority of citizens. This is particularly problematic for populations living in low- and middle-income countries.
Notably, this market price sharply contrasts with the cost of producing generic Lenacapavir. Independent research suggests that the actual production cost per person per year could be $35-46 USD, and under conditions of increased demand (mass production), this figure could potentially drop to as low as $25 USD. This represents a significant disparity between production cost and market price. The difference in prices is an active subject of discussion among international health organizations and pharmaceutical companies.
Global and Ethical Issues
The high cost of Lenacapavir directly impacts HIV prevention programs for low- and middle-income countries. If the drug is not widely accessible due to financial barriers, its potential to curb the global epidemic cannot be fully realized. This creates an ethical dilemma: a medical achievement that could save countless lives would only be available to wealthy countries or a small fraction of the population.
Therefore, UNAIDS and WHO are actively urging pharmaceutical companies (specifically Gilead Sciences, the drug’s manufacturer) to collaborate with governments. The goal is to establish fair pricing policies, sign licensing agreements (e.g., rights for generic version production), and develop distribution strategies to ensure the drug is rapidly and equitably distributed worldwide.
Future Prospects and Long-Term Goals
Lenacapavir is indeed a crucial innovation in the fight against the HIV epidemic. Its innovative mechanism and long-acting nature enhance preventive capabilities. If accessibility issues are resolved through fair pricing, licensing agreements, and international cooperation, Lenacapavir could prove decisive in the global fight against the HIV epidemic.
Sources:
WHO. (2025). FDA approval of injectable lenacapavir marks progress for HIV prevention.
WHO. (2024). Long-acting injectable lenacapavir proves effective in HIV prevention for women.
WHO. (2024). Long-acting injectable lenacapavir continues to show promising results for HIV prevention.
UNAIDS. (2025). The United States Food and Drug Administration approves long-acting injectable lenacapavir for HIV infection around the world.
